Cat 1 — 2026Skin & hairLongevity

Matrixyl

Palmitoyl Pentapeptide-4 / Pal-KTTKS / Matrixyl 3000

Signal peptide that mimics collagen breakdown fragments to stimulate fibroblasts to produce collagen elastin and fibronectin. One of the most evidence-backed topical cosmetic peptides with replicated human RCT data.

Evidence

Strong clinical data

Routes

topical

Available since

Developed by Sederma. Commercial use from early 2000s. One of the longest-used evidence-backed cosmetic peptides.

Mechanism of action

Mimics collagen breakdown fragments called matrikines that signal to fibroblasts that collagen needs to be made. Stimulates type I III and IV collagen synthesis fibronectin and hyaluronic acid production. Communicates through the extracellular matrix signaling system.

Effects in the body

Matrixyl works by mimicking the breakdown products of collagen which signals fibroblasts to produce more. Multiple human RCTs measuring actual wrinkle depth reduction make it one of the most evidence-backed cosmetic peptides in the world.

Pros & cons (from the literature)

Pros

Multiple human RCTs with wrinkle depth measurement data
Stimulates multiple ECM proteins simultaneously
One of the most validated cosmetic peptides available
Widely available and cost effective
Synergistic with Argireline and GHK-Cu

Cautions

Cosmetic only no systemic effects
Requires sustained daily use
Effects accumulate slowly over weeks to months
Palmitoyl attachment affects penetration quality
Many products underdose

Protocol summary (from published research)

Topical 2-8% concentration applied twice daily. Penetration enhanced with slightly acidic pH formulations pH 4.5-5.5. Matrixyl 3000 combination product shows additive effects.

Dosing ranges reproduced from published research literature. Not a prescription, not medical advice.

FDA & regulatory status

Cosmetic ingredient — no drug approval required. One of the most commercially validated topical peptides with genuine replicated clinical evidence. Safe and widely used.

Evidence base

Robinson et al. 2005 double-blind RCT published. Lintner et al. 2002 published. Well replicated in independent studies. Strong commercial evidence base.

Primary research sources

Peer-reviewed literature referenced throughout this profile is drawn from PubMed, Cell Metabolism, and clinical trial registries cited in the evidence base above.

Important. ThePeptide.expert summarizes published research. We are not a pharmacy, do not prescribe, and make no therapeutic claims. Regulatory status varies by jurisdiction.